In today’s session SPDR S&P Biotech (ETF) (XBI) recorded an unusually high (1,596) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious XBI decrease. With 1,596 contracts traded and 3064 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: XBI170120P00063330 closed last at: $2.75 or 16.7% down. SPDR S&P Biotech (ETF) (NYSEARCA:XBI) has risen 15.28% since April 25, 2016 and is uptrending. It has outperformed by 9.26% the S&P500.
SPDR S&P Biotech ETF seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The ETF has a market cap of $3.23 billion. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. It has a 3.55 P/E ratio. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
More notable recent SPDR S&P Biotech (ETF) (NYSEARCA:XBI) news were published by: Bloomberg.com which released: “Options Insight: How to Trade the SPDR S&P Biotech ETF” on October 06, 2016, also Investorplace.com with their article: “Buy the SPDR S&P Biotech (ETF) (XBI) TODAY â€“ Here’s Why” published on November 09, 2016, Investorplace.com published: “Try the SPDR S&P Biotech (ETF) (XBI) if You’re Bullish on the Biotech Pause” on November 16, 2016. More interesting news about SPDR S&P Biotech (ETF) (NYSEARCA:XBI) were released by: Benzinga.com and their article: “Dan Nathan’s SPDR S&P Biotech ETF Trade” published on October 24, 2016 as well as Investorplace.com‘s news article titled: “SPDR S&P Biotech (ETF) (XBI): Embrace the Biotech Bulls’ Return” with publication date: August 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.